通过融合白蛋白结合域延长抗CD47纳米抗体的半衰期

高晓娟; 娜斯拜·阿卜杜瓦哈普; 马晓玲; 王鲁娟; 王飞; 李江伟

doi:10.13568/j.cnki.651094.651316.2020.02.26.0002

您当前的位置：

首页 >

文章列表页 >

通过融合白蛋白结合域延长抗CD47纳米抗体的半衰期

生命科学与技术 | 更新时间：2026-01-21

- 通过融合白蛋白结合域延长抗CD47纳米抗体的半衰期
- 通过融合白蛋白结合域延长抗CD47纳米抗体的半衰期
- 新疆大学学报（自然科学版中英文） 2021年38卷第1期页码：69-75
- 作者机构：
  
  1. 新疆大学生命科学与技术学院新疆生物资源基因工程重点实验室
  2. 新疆优迈生物技术有限公司
- 作者简介：
- 基金信息：
  
  国家自然科学基金面上项目（315709357）
- DOI：10.13568/j.cnki.651094.651316.2020.02.26.0002
  中图分类号： R392-33
- 纸质出版：2021
- 稿件说明：
移动端阅览
[1]高晓娟,娜斯拜·阿卜杜瓦哈普,马晓玲,等.通过融合白蛋白结合域延长抗CD47纳米抗体的半衰期[J].新疆大学学报(自然科学版)(中英文),2021,38(01):69-75.
[1]高晓娟,娜斯拜·阿卜杜瓦哈普,马晓玲,等.通过融合白蛋白结合域延长抗CD47纳米抗体的半衰期[J].新疆大学学报(自然科学版)(中英文),2021,38(01):69-75. DOI： 10.13568/j.cnki.651094.651316.2020.02.26.0002.

DOI：10.13568/j.cnki.651094.651316.2020.02.26.0002.

摘要

纳米抗体是一类在生物医药中具有重要应用前景的蛋白药物

然而由于其分子过小极易被清除.为了获得更好的体内代谢

我们通过CD47纳米抗体融合表达白蛋白结合域(ABD)

从而提高其体内半衰期.使用分子克隆技术合成构建带有CD47-ABD基因的原核表达载体pET22b-3D3-2-ABD

转入BL21(DE3)中进行表达及Ni+亲和层析柱纯化

并使用酶联免疫吸附剂(ELISA)法测定其生物学活性.给小鼠尾静脉注射融合蛋白后在不同时间点采血

用双抗体夹心ELISA测定融合蛋白的血浆浓度

并计算药代动力学参数.获得了pET22b-3D3-2-ABD重组质粒

并在BL21(DE3)表达了CD47-ABD融合蛋白.通过Ni+亲和柱纯化

获得了较高纯度和浓度的CD47-ABD融合蛋白;改造后的CD47-ABD融合蛋白仍保留抗原结合活性

与CD47抗原及人血清白蛋白(HSA)的结合活性均具有剂量依赖性.CD47-ABD融合蛋白的半衰期从改造前的35.82 min延长至了501.52 min.本研究证明了融合ABD能够显著延长CD47纳米抗体体内半衰期而不影响其抗原结合

为解决纳米抗体自身半衰期短的缺点提供了理论和技术参考.

Abstract

Nanobody is a promising class of biopharmaceuticals with high potential for future therapeutic applications. However

due to their small size they are rapidly cleared from circulation. To improve its pharmacokinetics properties

a CD47 binding nanobody was fused with albumin binding domain(ABD) for extending the half-life in vivo. The prokaryotic expression vector pET22b-3D3-2-ABD with CD47-ABD gene was synthesized and constructed by molecular cloning technology. It was transferred into BL21(DE3) for expression and purified by Ni+ affinity chromatography

and its biological activity was determined by enzyme-linked immunosorbent assay(ELISA). Blood was collected at different time points after mice were injected with the fusion protein into the tail vein. The plasma concentration of the fusion protein was measured by a double antibody sandwich ELISA

and the pharmacokinetic parameters were calculated. The recombinant plasmid pET22b-3D3-2-ABD was obtained and CD47-ABD fusion protein was expressed in BL21(DE3). The high purity and concentration of CD47-ABD fusion protein were obtained by Ni+ affinity column purification. The modified CD47-ABD fusion protein have similar antigen binding activity compare with CD47 nanobody

and possess serum albuminis binding activity in dosedependent manner. The half-life of CD47-ABD fusion protein was extended from 35.82 min to 501.52 min. The experiment demonstrate that the ABD fusion is a promising approach to increase the half-life of CD47 nanobody without affecting their antigen binding efficacy. It strongly suggests that the ABD fusion strategy can be potentially used as a universal method to improve the pharmokinetics properties of nanobodies.

关键词

Keywords

references

陆融,王卓,姚智.小分子多肽抗肿瘤作用的研究进展[J].天津医科大学学报,2005,11(3):499-502.LU R,WANG Z,YAO Z.Research progress in antitumor effect of small molecular polypeptides[J].Journal of Tianjin Medical University,2005,11(3):499-502.(in Chinese)

周浩泽,沈子龙,徐寒梅.蛋白多肽类药物药代动力学分析方法研究进展[J].药学进展,2017,41(8):592-599.ZHOU Z H,SHEN Z L,XU H M.Recent progress in pharmacokinetic analysis of protein and peptide drugs[J].Progress in Pharmaceutical Sciences,2017,41(8):592-599.(in Chinese)

FAN K L,JIANG B,GUAN Z,et al.Fenobody:A ferritin-displayed nanobody with high apparent affinity and half-life extension[J].Analytical Chemistry,2018,90(9):5671-5677.

梁成罡,王军志.长效蛋白生物药研究进展[J].中国新药杂志,2014,23(20):2388-2393.LIANG C G,WANG J Z.Research progress of long-acting protein therapeutics[J].Chinese Journal of New Drugs,2014,23(20):2388-2393.(in Chinese)

INADA Y,FURUKAWA M,SASAKI H,et al.Biomedical and biotechnological applications of PEG-and PM-modified proteins[J].Trends in Biotechnology,1995,13(3):86-91.

路娟,刘清飞,罗国安,等.药物的聚乙二醇修饰研究进展[J].有机化学,2009,19(8):213-216.LU J,LIU Q F,LUO G A,et al.Advances in PEGylation of drug conjugates[J].Chinese Journal of Organic Chemistry,2009,19(8):213-216.(in Chinese)

MULLER D,KARLE A,MEISSBURGER B,et al.Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin[J].Journal of Biological Chemistry,2007,282(17):12650-12660.

GRISHIN ALEXANDER V,SHESTAK NIKITA V,LAVROVA NATALIA V,et al.Fusion of lysostaphin to an albumin binding domain prolongs its half-life and bactericidal activity in the systemic circulation[J].Molecules,2019,24(16):2892.

CHAUDHURY C,MEHNAZ S,ROBINSON J M,et al.The major histocompatibility complex-related fc receptor for igg (fcrn)binds albumin and prolongs its lifespan[J].Journal of Experimental Medicine,2003,197(3):315-322.

FERRANDIS E,PRADHANANGA S,TOUVAY C,et al.Immunogenicity,toxicology,pharmacokinetics and pharmacodynamics of growth hormone ligand-receptor fusions[J].Clinical Science,2010,119(11):483-491.

李成媛,张晶晶,钱凯,等.人血清白蛋白-干扰素α2b融合蛋白在CHO细胞中的表达[J].中国生物工程杂志,2016,36(7):7-14.LI C Y,ZHANG J J,QIAN K,et al.Expression of human serum albumin interferonα2b fusion protein in cho cells[J].China Biotechnology,2016,36(7):7-14.(in Chinese)

李芝芹,邱爽,雷楗勇,等.重组人血清白蛋白-干扰素β融合蛋白的分离纯化及质控方法的建立[J].中国生物制品学杂志,2012(10):1325-1328.LI Z Q,QIU S,LEI J Y,et al.Isolation,purification and development of method for quality control of recombinant human serum albumin-interferonβfusion protein[J].Chin J Biologicals,2012(10):1325-1328.(in Chinese)

MELDER R J,OSBORN B L,RICCOBENE T,et al.Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice[J].Cancer Immunology Immunotherapy,2005,54(6):535-547.

MALM M,BASS T,GUDMUNDSDOTTER L,et al.Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension[J].Biotechnology Journal,2014,9(9):1215-1222.

JONSSON A,DOGAN J,HERNE N,et al.Engineering of a femtomolar affinity binding protein to human serum albumin[J].Protein Engineering Design and Selection,2008,21(8):515-527.

SICK E,JEANNE A,SCHNEIDER C,et al.CD47 update:a multifaceted actor in the tumour microenvironment of potential therapeutic interest[J].British Journal of Pharmacology,2012,167(7):1415-1430.

王玉树,周兆平,苏庆宁.靶向CD47的抗肿瘤抗体研究进展[J].国际肿瘤学杂志,2013,40(11):817-820.WANG Y S,ZHOU Z P,SU Q N.Anti-tumor antibodies targeting CD47[J].Journal of International Oncology,2013,40(11):817-820.(in Chinese)

LO,JESSICA,LAU,et al.Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma[J].Liver International,2016,36(5):737-745.

MANNA P P,FRAZIER W A.CD47 mediates killing of breast tumor cell via Gi-dependent inhibitor of protein kinase A[J].Cancer Research,2004,64(3):1026-1036.

CHEN Q,FANG X,JIANG C,et al.Thrombospondin promoted anti-tumor of adenovirus-mediated calreticulin in breast cancer:Relationship with anti-CD47[J].Biomedicine&Pharmacotherapy,2015,73:109-115.

鞠宝辉,黄宇婷,田菁,等.抗CD47单克隆抗体对卵巢癌细胞靶向治疗的体外研究[J].中国肿瘤临床,2013(8):18-21.JU B H,HUANG Y T,TIAN J,et al.In vitro application of anti-CD47 monoclonal antibody for targeted therapy of ovarian cancer[J].Chin J Clin Oncol,2013(8):18-21.(in Chinese)

LIU J,WANG L,ZHAO F,et al.Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential[J].Plos One,2015,10(9):e0137345.

EDRIS B,WEISKOPF K,WEISSMAN I L,et al.Flipping the script on macrophages in leiomyosarcoma[J].Onco Immunology,2012,1(7):1202-1204.

WILLINGHAM S B,VOLKMER J P,GENTLES A J,et al.The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors[J].Proceedings of the National Academy of Sciences of the United States of America,2012,109(17):6662-6667.

JACOBS S A,GIBBS A C,CONK M,et al.Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics[J].Protein Engineering Design and Selection,2015,28(10):385.

张瑜,赵述强,姚文兵.融合蛋白技术在长效药物开发中的应用[J].药学进展,2013,37(9):454-459.ZHAN Y,ZHAO S Q,YAO W B.Application of fusion protein technique in development of long-acting drugs[J].Progress in Pharmaceutical Sciences,2013,37(9):454-459.(in Chinese)

郑炜,李杰.人血清白蛋白融合技术研究进展[J].长沙大学学报,2013(5):16-19.ZHENG W,LI J.Progress in fusion technology of human serum albumin[J].Journal of Changsha University,2013(5):16-19.(in Chinese)

GUO R,GUO W,CAO L,et al.Fusion of an albumin-binding domain extends the half-life of immunotoxins[J].International Journal of Pharmaceutics,2016,511(1):538-549.

浏览量

529

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据